
Opinion|Videos|May 9, 2025
CHE: Symptoms and Diagnosis
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how chronic hand eczema (CHE) diagnosis relies on clinical features such as erythema, scaling, vesicles, hyperkeratosis, fissures, and erosions, which must be distinguished from atopic dermatitis through a comprehensive patient history and full-body examination.
Advertisement
Video content above is prompted by the following:
CHE Clinical Features and Diagnosis
Key Themes:
- Key clinical signs: Erythema, scaling, edema, vesicles, hyperkeratosis, fissures, and erosions, with more chronic than acute presentation.
- Differential diagnosis: Distinguishing CHE from atopic dermatitis requires a holistic history and full-body examination.
- Predominant symptoms: Beyond itching, skin pain represents a significant burden, particularly from fissures and cracking.
Notable Insights:
Dr Chovatiya emphasized that "from a patient perspective...a focus on skin pain as well as some of the cracking, bleeding, opening of skin, and wounding is going to be extraordinarily vital to really understanding the patient’s perspective."
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD
4
SUMMIT Substudy Reveals Tirzepatide’s Impact on LV, Atrial Metrics of HFpEF
5

